Navigation Links
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
Date:10/2/2008

- Two Milestones Reached in Zonisamide Patent Portfolio -

SAN DIEGO, Oct. 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced the initiation of its first clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine. The Phase 2a clinical trial, OZ-101, is designed to examine the effectiveness of OREX-003 in mitigating drug-associated weight gain and/or other metabolic consequences commonly experienced by patients taking atypical antipsychotic medications, as well as the potential enhancement of antipsychotic activity.

In additional Company news, the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,425,571 providing broad coverage of the use of zonisamide either alone or in combination with other drugs for the treatment of obesity through 2023. The USPTO has also issued U.S. Patent No. 7,429,580 which broadly covers zonisamide in combination with various marketed atypical antipsychotics including olanzapine, clozapine, risperidone, quetiapine, aripiprazole and ziprasidone through 2025. We believe that these patents complement each other and provide a strong patent portfolio for OREX-003. Orexigen has licensed both patents on an exclusive basis from Duke University.

"The initiation of the OZ-101 clinical trial and progress in securing comprehensive intellectual property coverage for zonisamide are important milestones for Orexigen as we grow our product candidate pipeline beyond our initial obesity programs by extending into other central nervous system disorders," said Gary Tollefson, M.D.,
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Today the Academy of ... United States Court of Appeals for the D.C. Circuit challenging ... published in the Federal Register on June 25, 2014. ... contrary to the text and intent of the FAA Modernization ... Congress’ specific prohibition on any new rules or regulations regarding ...
(Date:8/22/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... 30, 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have ... June 30, , Six-months ended June 30, ( ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 ...
(Date:8/22/2014)... University of Surrey have discovered how the receptors responsible ... genes. , The new study, published today in ... activity in turn regulates the cycle of all cells ... that the local biological clock and its control are ... clock in bladder physiology and ageing. , ...
(Date:8/22/2014)... a study published today (August 22nd), in the ... the Champalimaud Neuroscience Programme establish the effect of ... of advanced genetic and optical techniques., "Serotonin is ... a wide range of brain functions, from the ... of complex emotional behaviours, This neurotransmitter is also ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2From happiness to pain: Understanding serotonin's function 2
... Wis. -- Gov. Jim Doyle says taxpayers will ... total of nearly $80 million over the lifetime of ... and services, including a number of technology areas. , ... Accountability, Consolidation, and Efficiency (ACE) Initiative to ensure ...
... of Milwaukee is one of six first-year college students from ... Online's "Project Freshman," a new documentary series that will be ... Friday, Sept. 23. New episodes will air every Thursday. The ... were given digital video cameras and were trained in their ...
... -- The Wisconsin Technology Council has teamed with PropertyDrive, ... database of commercial real estate on the Tech Council ... on the site's Resource Center, Commercial Property Search. , ... locate or expand in Wisconsin the ability to search ...
Cached Biology Technology:
(Date:8/22/2014)... 22, 2014 ... announced the addition of the  "Biometrics ... to their offering.       ... a technology that helps in the ... physical or behavioral features. It involves ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information for ... University of California, Riverside in its 2014 list of ... times." , To generate the list, the company analyzed ... whose published work has had enormous impact. , The ... individuals who published the greatest number of highly cited ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... is available in Polish . A ... mouse embryos can repair damaged brain circuitry and partially normalize ... obese due to a genetic deficiency. This proof-of-principle discovery represents ... which researchers hope might one day be used to repair ...
... National Taiwan University researchers have successfully manipulated the life span ... remove and restore protein functions related to yeast aging. ... in yeast acts like a life span clock: It is ... age. In a report in the September 16 edition ...
... and the University of Geneva have discovered a genetic mechanism ... genes play only a secondary role. The research published in ... mechanism is found in a DNA sequence that was thought, ... enhancers which, when combined with one another, modulate the activity ...
Cached Biology News:Metabolic defects in mice corrected with transplanted embryonic neurons 2Hopkins scientists turn on fountain of youth in yeast 2Finger (mal)formation reveals surprise function of desert DNA 2
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: